VA7 is a neurotropic alphavirus vector based on an attenuated strain of Semliki Forest virus. We have previously shown that VA7 exhibits oncolytic activity against human melanoma xenografts in immunodeficient mice. The purpose of this study was to determine if intravenously administered VA7 would be effective against human glioma.
In vitro, U87, U251, and A172 human glioma cells were infected and killed by VA7-EGFP. In vivo, antiglioma activity of VA7 was tested in Balb/c nude mice using U87 cells stably expressing firefly luciferase in subcutaneous and orthotopic tumor models. Intravenously administered VA7-EGFP completely eradicated 100% of small and 50% of large subcutaneous U87Fluc tumors. A single intravenous injection of either VA7-EGFP or VA7 expressing Renilla luciferase (VA7-Rluc) into mice bearing orthotopic U87Fluc tumors caused a complete quenching of intracranial firefly bioluminescence and long-term survival in total 16 of 17 animals. In tumor-bearing mice injected with VA7-Rluc, transient intracranial and peripheral Renilla bioluminescence was observed. Virus was well tolerated and no damage to heart, liver, spleen, or brain was observed upon pathological assessment at three and ninety days post injection, despite detectable virus titers in these organs during the earlier time point.
Citation: Heikkilä JE, Vähä-Koskela MJV, Ruotsalainen JJ, Martikainen MW, Stanford MM, McCart JA, et al. (2010) Intravenously Administered Alphavirus Vector VA7 Eradicates Orthotopic Human Glioma Xenografts in Nude Mice. PLoS ONE 5(1): e8603. https://doi.org/10.1371/journal.pone.0008603
Editor: Torbjorn Ramqvist, Karolinska Institutet, Sweden
Received: April 22, 2009; Accepted: December 5, 2009; Published: January 6, 2010
Copyright: © 2010 Heikkilä et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by K. Albin Johanssons Stiftelse, Medicinska Understödsföreningen Liv och Hälsa, Stiftelsens for Åbo Akademi Forskningsinstitut, The Finnish Cancer Organizations, and The Cancer Society of South-Western Finland. JCB is supported by the Canadian Institutes of Health Research and Terry Fox Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: JCB is a co-founder of Jennerex Biotherapeutics and sits on the Board of Directors.
During the past decades malignant gliomas have presented with an insurmountable obstacle in cancer treatment. While recent results of a multi-center phase III clinical trial combining radiotherapy (RT) with the DNA-alkylating agent temozolomide (TMZ) have marked a true paradigm shift in treatment of glioblastoma multiforme (GBM) , the most common type of malignant glioma, patients rarely live beyond two years after diagnosis and there are no cures. Radical surgery can alleviate the effects of excess tumor burden and prolong meaningful life-span, but remains palliative only .
One of the biggest reasons for the grim prognosis is the highly invasive nature of gliomas. Glioma cells can migrate long distances in the brain parenchyma and establish satellite lesions even in the contralateral hemisphere . Other reasons for treatment failure are the vast genotypic and phenotypic heterogeneity of malignant gliomas, limiting the effectiveness of any single therapeutic on a population-wide scale, and the presence of tumorigenic cells capable of both resisting conventional therapies as well as escaping immune surveillance . Recently, tumor-initiating cells (TICs) were indentified in malignant gliomas . These cells were later shown to be resistant to ionizing radiation which could well explain why radiation therapy fails to kill malignant gliomas .
Oncolytic viruses hold great promise as glioma-killing agents. Reovirus , Newcastle disease virus (NDV) , Herpes simplex virus-1 (HSV-1) , , adenovirus , vesicular stomatitis virus (VSV) , measles virus , myxoma virus , poliovirus  and vaccinia virus  have emerged as potential vehicles to combat malignant glioma and have shown oncolytic activity against human glioma xenografts. However, while oncolytic viruses must be able to kill cancer cells, they should leave normal healthy cells unharmed. To achieve this, HSV-1 , adenovirus  and vaccinia virus  have been engineered to selectively replicate only in tumor cells. Other oncolytic viruses including reovirus, measles virus, VSV and NDV, seem to have an inherent capability to specifically replicate only in tumor cells, leaving normal cells largely unaffected. The tumor permissiveness of viral replication is often due to defects in the immunological/antiviral status of the tumor cells. Defects in the interferon response of tumor cells seem to explain the tumor-specificity of VSV  and NDV . Reovirus replication, on the other hand, is restricted to cells with activated Ras signaling pathway .
Semliki Forest virus (SFV) is an enveloped, positive stranded RNA virus of the family Togaviridae . The natural hosts of SFV are small rodents and birds while mosquitoes are the usual vector. Human infections are also common and in certain parts of Africa up to 40% of the population has been shown to be seropositive –. Semliki Forest virus infection does not associate with any disease in humans but it may cause mild symptoms such as headache, fever and rash . Several different strains of SFV exist, some of which are highly virulent for laboratory mice, while others are virulent only for neonatal mice. The A7(74) strain of SFV is a naturally attenuated strain – which, like the virulent wild type strains L10 and SFV4, is neurotropic, infecting both neurons and glial cells, but unlike the these strains which induce fatal encephalitis in mice irrespective of their age, A7(74) is lethal only for newborn mice , . In mice older than two weeks, replication of A7(74) in neurons is severely restricted and the mice survive the infection without neurological sequealae . The mechanism of neuronal restriction of replication is yet unknown but has been shown to be independent of type I interferon signaling .
We have constructed a replication-competent expression vector VA7-EGFP based on the A7(74) virus . VA7-EGFP has been shown to replicate in and kill a number of cultured tumor cells similar to SFV4 and to be able to deliver therapeutic genes into the CNS of diseased mice upon intraperitoneal injection . In a recent report, we have described the oncolytic potential of VA7-EGFP against human melanoma xenografts in severe combined immunodeficient (SCID) mice .
Given the oncolytic potential and CNS tropism of VA7 upon peripheral administration, it was of interest to investigate whether VA7 would be able to inhibit the growth of human glioma xenografts implanted either subcutaneously or orthotopically in nude mice. In the present report we show that intravenously administered VA7 virus effectively eradicated both subcutaneous and orthotopic U87MG tumor xenografts in nude Balb/c mice. Besides initial transient viremia none of the mice displayed any neurological symptoms or signs of pathology.
VA7-EGFP–Induced Oncolysis in Glioma Cell Lines
U87, U251 and A172 cell lines were all infected by VA7-EGFP (Figure 1B) but the rate of spread was different in each one. Cell viability assay showed that U87 cells were killed within 96 hours at very low MOI values with 42% of the cells being alive at MOI 0.001 and at MOI 0.1 only 1.8% of the cells were viable at this time point (Figure 1A). U251 cells required a 100-fold higher viral dose to achieve a similar degree of cell death with 53.4% of the cells alive at MOI 0.1 and 4.1% alive at MOI 10. The sensitivity of A172 cells to VA7-EGFP fell between the other two glioma cell lines with 36.4% of the cells being viable at MOI 0.01 (Figure 1A). Viral replication in the infected cells was confirmed by Western blot analysis of viral structural proteins. In all cell lines, the 30 kDa capsid, 50 kDa E1 and E2 proteins as well as the p62 precursor protein were abundantly expressed, confirming productive infection (Figure 1C).
(A) Dose-dependent killing by VA7-EGFP of U87, U251 and A172 glioma cells in culture. Glioma cells were seeded in a 96-well plate and VA7-EGFP at MOI ranging from 10−5 to 101 was added 16 hours later. Cell viability was assessed 96 hours later using calcein AM as indicator of cell membrane integrity. The mean values and standard deviations are shown. (B) Photograph of the cells at 96 hours post infection with VA7-EGFP at MOI 0.1. Fluorescence channel for VA7-EGFP shows GFP-positive cells indicative of active virus replication. (C) Western blot of VA7 structural protein expression in untreated and VA7-EGFP -infected cells 18 hours post infection. Equal number of cells were infected at MOI 1 and collected for Western analysis 18 hours later. In all cell lines the 30 kDa capsid, the E1 and E2 50 kDa proteins and the E2 precursor p62 were abundantly expressed.
Characterization of Luciferase Expressing U87 Cells
U87 cells transduced with the lentiviral vector WPTFluc at MOI 1, 5, 25 and 50 exhibited Fluc activity which increased linearly with increasing virus dose (Figure S1A). Fluc expression did not affect cell proliferation as compared to non-transduced control cells (Figure S1B) and we chose to use U87 cells that had been transduced at MOI 25 for subsequent studies. Fluc expression did not change the sensitivity of the U87Fluc cells to VA7-EGFP –induced cell killing as compared to parental U87 cells (Figure S1C). Flow cytometry analysis showed that at least 94% of the cells in U87Fluc cell population were Fluc positive (Figure S1D).
Oncolytic Efficacy of VA7-EGFP in Subcutaneous Nude Mouse Model
When the subcutaneous tumors had reached average sizes of either 96.5 mm3 (small) or 442 mm3 (large), the mice were injected intravenously in the tail vein with 106 PFU of VA7-EGFP. Median survival of mice treated with PBS was 26 days (95% CL = 25 days to 28 days) at which time point the tumor size had reached 1040 mm3 (95% CL = 732 mm3 to 1344 mm3) (Figure 2A, B) and the animals were sacrificed. For the small tumors, a single injection of the virus led to complete and lasting tumor eradication in all of the 5 treated animals over a 4-month follow-up period (Figure 2A). A single intravenous injection of the virus in mice harboring large tumors produced one full cure out of six with a median survival time of 49 days (95% CL = 41 days to 53 days) and a significant increase in survival compared to the PBS-treated group (log-rank test, P<0.01) (Figure 2A,B). Three weekly injections with VA7-EGFP yielded three out of six cures (median survival not reached), also with a significant increase in survival (log-rank test, P<0.005) (Figure 2A,B). VA7-EGFP did not induce any neurological or other symptoms in the treated mice, and no effect on animal weight was observed (Figure S2).
(A) U87Fluc cells (5×106) were implanted subcutaneously in nude mice and when the tumors had grown to an average size of 100 mm3, the animals were given a single intravenous injection of either PBS or 1×106 PFU of VA7-EGFP. In another two groups, the tumors were allowed to grow until they reached an average size of 450 mm3 and the animals were given either a single intravenous injection of 1×106 PFU of VA7-EGFP or three injections of the virus at 7-day intervals, each 1×106 PFU. (B) Kaplan-Meier survival analysis of mice with subcutaneous U87Fluc xenografts and treated with either PBS or intravenous injections of VA7-EGFP.
Histological examination of tumors isolated 7 days after a single injection with VA7-EGFP showed wide-spread necrosis with only very few regions of Fluc positive live tumor cells which were located next to an SFV-positive region implying that the viral infection was still proceeding (Figure 3A). While those xenografts that regrew after three weekly doses of virus were large at study end point, Fluc positive cells were still restricted to the periphery of the tumors (Figure 3B). In parallel HE-stained sections the bulk of the tumors appeared necrotic (Figure 3B, insert). In contrast, tumors isolated from untreated animals showed widespread distribution of live, Fluc positive tumor cells with necrotic areas detected mainly in the very core of the tumor sample (Figure 3C).
Anti-SFV immunostaining, anti-luciferase staining and H&E staining, respectively, of parallel sections of residual tumor tissue in a mouse 7 days after injection with a single intravenous dose of 1×106 PFU of VA7-EGFP (A) or 21 days after the third injection of VA7-EGFP (B) (original magnification ×200, insert ×10). (C) Similar staining of a xenograft from a PBS-treated tumor-bearing mouse. n = necrotic tissue, l = live cells. Bar = 5 mm.
Assessment of the Presence of Virus-Resistant Cells in Regrowing Tumors
In order to study whether tumor regrowth after initial regression was due to emergence of virus-resistant cells, we established several explant cell lines from treated regrowing tumors as well as PBS-treated tumors, and infected them with different concentrations of stock virus. All explant cell lines were Fluc positive as judged from staining with anti-luciferase antibody (Figure S3A). Despite quantitative differences in the sensitivity to virus-induced cell killing between the explanted cells and the parental U87Fluc cells at MOI values between 0.001 and 0.01, all explant cell lines from treated-tumors were more sensitive to VA7-EGFP than cell lines isolated from PBS-treated tumors (Figures S3B). Hence, the failure of VA7-EGFP to eradicate a portion of the larger tumors was not due to virus-resistant glioma cells as observed previously using VA7-EGFP in a human melanoma model .
Oncolytic Efficacy of VA7-EGFP in Orthotopic Nude Mouse Model
Mice with established intracranial tumors assessed by IVIS were either given an intravenous injection of PBS (CTRL) or treated with a single intravenous injection of 1×106 PFU of VA7-EGFP. Median survival of animals treated with PBS was 36 days (95% CL = 26 days to 42 days) at which time the Fluc end point value of 109 photons/sec/cm2/steradian was reached (approximately one week before the onset of neurological symptoms). In the VA7-EGFP-treated mice, Fluc signal was completely quenched within 6 days after virus injection, remaining undetectable in all 5 mice during the 100-day follow-up (Figure 4). Neither weight loss nor neurological symptoms were observed, and we also did not find any persistent virus in the CNS of these animals by titration (data not shown).
U87Fluc cells (2×105) were implanted stereotactically in nude mice. Tumor growth was monitored by measuring the light produced by the tumor cells with a cooled CCD camera after the animals had been injected with luciferin. Sixteen days post tumor implantation 5 mice harboring intracranial tumors received a single i.v. injection of 1×106 PFU of VA7-EGFP. Tumor signal was extinguished within 6 days and remained below detection limit until the end of the study. A PBS-treated mouse is provided as comparison (CTRL).
Replication of VA7-Rluc in Naïve and Tumor-Bearing Mice
To study the virus biodistribution we infected 11 naïve mice with 1×106 PFU of VA7-Rluc. The animals were sacrificed at days 3, 6 and 9 post infection and brains, heart, liver and spleen were removed for titration and histology. Virus was detected in all analyzed organs at day 3 but exclusively in the brain at day 6. No virus was recovered from any organ beyond this time point (Table 1). Histological assessment of the organs at day 3 revealed no histopathological changes (Figure S7).
To relate the viral titers to ectopic expression of Renilla luciferase we injected 6 mice bearing intracranial tumors with VA7-Rluc. We used ViviRen substrate, shown to give bioluminescence signals up to three times higher than coelenterazine, the natural substrate of Rluc . Between 16 and 40 hours post injection, five animals exhibited Rluc which co-localized with tumor-derived Fluc (for complete time course see Figure S4). In four animals transient Rluc expression could be observed in peripheral organs (Figure 5A). Tumor signal was undetectable in all mice by 4 days post injection, but reappeared in one mouse (mouse 1) at day 24, only to regress again and remain absent at the final measurement 101 days post injection (Figure S4). All the animals treated intravenously with either VA7-EGFP or VA7-Rluc virus were alive at 120 days post implantation (Figure 5B), and all except one (mouse 5) scored negative for tumor signal. Post mortem histology of the brain of this Fluc-positive animal revealed one larger cluster of firefly luciferase expressing tumor cells (Figure 5C). An ongoing wound healing process was also apparent, although at a relatively long distance from the residual tumors (Figure 5C). No Fluc positive cells were found in the brains of the other 5 animals and in addition to mouse 5, signs of tissue trauma were evident also in the brain of mouse 6 (Figure S5). In both cases, these regions were most likely the original tumor sites. We also examined the brains of all tumor-bearing mice which had received VA7-Rluc for the presence of SFV antigen, but no persistent virus could be detected (result shown for mouse 5 in Figure 5C).
(A) Orthotopic U87Fluc xenografts were established in Balb/c nude mice by stereotactic injections of the tumor cells. When the firefly bioluminescence from the tumor xenografts reached appropriate levels the animals were given an intravenous injection of 1×106 PFU of VA7-Rluc. After 24 hours, the animals were injected intravenously with ViviRen substrate and the light produced by the VA7Rluc vector was monitored by a cooled CCD camera. Transient virus replication (Rluc) could be detected in the brain, co-localizing with the tumor (Fluc), as well as in the periphery. Even tumors close to endpoint were fully eradicated. Virus signals can be compared with each other but not with tumor signal due to different intensity scale. (B) Long-term survival of mice in Figure 4 and Figure 5A. None of the animals treated intravenously with either VA7-EGFP or VA7-Rluc reached the end point bioluminescence value. The median survival of PBS-treated (CTRL) mice was 36 days (95% CL = 26 days to 42 days) and all differences to this group were highly significant (log-rank test, P<0.0001). (C) Sagittal section of the brain of mouse 5 stained against Fluc (top left). This mouse was given a single intravenous dose of 1×106 PFU of VA7-Rluc and was the only one in the group of intravenously -treated mice that produced an intracranial Fluc IVIS signal at the final measurement of the experiment. Top right, 20× magnification of box 1 showing a Fluc-positive cell cluster. Bottom left, 10× magnification of box 1 showing anti-SFV immunostaining of parallel brain section from the same mouse. No SFV immunoreactivity could be detected anywhere in the brain of this or any other i.v. treated mouse. Bottom right, 10× magnification of the region in box 2 from a parallel section stained with H&E. The increased cellular density surrounding the blood vessel in the picture is indicative of regenerative activity. This region was possibly the site of the original tumor before destruction by the VA7-Rluc virus.
We repeated the survival experiment with similar results. Only one out of 6 U87Fluc implanted and VA7Rluc –treated mice showed tumor regrowth after initial tumor regression. All other 5 animals survived 90 days after virus injection and histological assessment revealed no pathological changes in the organs studied (Fig. S7). Also, we were unable to detect virus in the treated mice at day 90 (Table 1). In contrast, immunohistochemical analysis of three tumor-bearing animals sampled at day 3 post virus injection revealed disseminated virus antigen in the intracranial tumors thus confirming productive infection of glioma xenografts (Fig. 6).
U87Fluc cells were implanted in the striatum Balb/c nude mice and tumor growth was monitored by magnetic resonance imaging. When tumors were visible mice were injected with 1×106 pfu of VA7-EGFP and sacrificed three days later. Brains were removed and paraffin sections prepared. (A–D) Representative images of U87Fluc xenograft immunostained against Fluc (A,C) and SFV antigen (B,D). (A,B) magnification, ×27; (B,D) 3.7× magnification of boxed areas in (A,B).
In the present paper we describe the oncolytic potential of the SFV vector VA7 in a nude mouse model of human glioma. The initial results that small subcutaneous tumors were completely eradicated by a single injection of VA7-EGFP were promising, but regrowth after initial regression of larger tumors was suggestive of emerging resistance, as seen in a human melanoma model . However, as the isolated explant cultures could be killed by VA7-EGFP, mechanisms other than resistance to VA7 are responsible for the failure to achieve complete eradication of large tumors.
The observation that larger tumors do not respond as well as smaller tumors to oncolytic virus is not new . For example, subcutaneous rhabdomyosarcoma , human lymphoma xenografts  and orthotopic gliomas  showed reduced response as tumor size increased. Apart from tumor-related barriers, such as connective tissue and increased interstitial pressure, the innate immune system is known to restrict virus spread and to cause premature virus clearance , . While SFV establishes a viremia that lasts up to 4 days, even nude mice clear the virus with kinetics similar to immunocompetent animals, mediated by serum IgM . Because attenuated SFV is cleared at a slower rate from the brain  it may be particularly well suited to target intracranial tumors.
A major reason for glioma recurrence is the invasion of the healthy brain parenchyma . Although the U87 nude mouse model is not generally considered invasive, sporadic tumor cells have been detected outside the main tumor mass and the model does recapitulate some of the other characteristics of human malignant glioma , . Also, the gene expression of U87 and U251 cells change towards a common profile when they are implanted orthotopically rather than subcutaneously , and only in orthotopically implanted U87 xenografts can purported CD133-positive brain tumor stem cells be detected . It was therefore encouraging to observe that a single intravenous injection of the VA7 virus was sufficient to fully cure the vast majority of the animals harboring orthotopic xenografts. Only one animal out of 17 intravenously-treated mice relapsed and only in one mouse residual tumor cells could be detected at the study end point. In comparison, intratumoral administration of reovirus , myxomavirus , intergeneric poliovirus  or chimeric HSV-1  has produced long term, tumor-free survivors in the range of 75 to 100%, but where studied, peripheral administration has produced none. Mutant VSV was recently shown to retard the growth of U87 orthotopic tumor xenografts after intravenous administration but all the animals eventually died of recurrent tumors . This was not likely due to poor virus penetration into the tumors, as in another study systemic administration of VSV effectively induced apoptosis in virtually all cells of orthotopic glioma xenografts .
It remains unclear whether the remaining Fluc-positive cells in the sole mouse displaying Fluc-signal at study end point (Figure S4, mouse 5) could have formed a viable tumor, as another tumor-bearing animal treated with VA7-Rluc and apparently tumor-free (Figure S4, mouse 1) presented later with recurrent Fluc signal that, however, eventually cleared and no remaining tumor cells were seen in the brain at the end of the study. Although we do not exclude the possibility that persisting virus in the brain re-infected the residual cells in this mouse, in contrast to previous reports using SFV A7(74) , . We could not find any evidence of VA7 virus persistence in the brains of the nude mice. This discrepancy might be explained by genetic differences between the cloned VA7 virus and the parental virus , .
A potential limitation of using systemic delivery of oncolytic viruses is replication outside the target tissue. In the present study, Renilla bioluminescence indicative of VA7 replication could be detected outside tumor tissue indicating that VA7 does not show strict tumor specificity which is not unexpected. This appears to be the case even for SFV replicons . We could not detect any Renilla bioluminescence in naïve mice (data not shown) which suggests that the sensitivity of Rluc imaging is not high enough to detect such low levels of virus as present in the organs of naïve mice. Plaque assay, however, revealed transient presence of virus in all analyzed organs but none of the treated animals displayed any neurological symptoms of infection and no histopathological changes were observed (Figure S7) showing that VA7 virus is a safe vector in adult hosts. This is corroborated by numerous studies both in animals and CNS model systems using parental SFV A7(74) , , , .
In conclusion, we have shown that replication-competent vector VA7 based on attenuated SFV effectively infects and kills human glioma tumors in nude mice while leaving healthy brain tissue unharmed. We want to stress, however, that because of the extreme susceptibility to VA7 of U87 cells, our experiments may give an overestimation of the oncolytic efficacy of this virus and should therefore be considered the best case scenario. Thus, this work is the prelude to studies addressing the oncolytic capacity of attenuated SFV in the presence of an intact immune system. If the results of this study can be validated in immunocompetent models, the possibility to administer the virus systemically and its natural capacity to pass the blood-brain-barrier are attractive features that may prove beneficial in clinical settings.
Materials and Methods
All animal work has been conducted according to relevant national and international guidelines. Approval has been obtained from the Finnish National Review Board for Animal Experimentation.
U87MG and A172 human glioma cell lines were obtained from the American Type Culture Collection (ATCC). U251 human glioma cells were obtained from Dr. J. Wahlfors (A.I. Virtanen Institute, Kuopio, Finland). The cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal calf serum at 37°C in 5% CO2. U87Fluc cells were established by lentiviral transduction using WPTFluc, constructed by replacing the GFP gene in WPTGFP (from Dr. D. Trono) with the luciferase gene from pMIR-REPORT™ plasmid (Ambion Inc., TX, USA).
Construction and Production of VA7 Vectors
Construction and production of VA7-EGFP has been described . VA7-Rluc was constructed by cutting the gene encoding Renilla luciferase from pRL-Null vector (Promega, Madison, WI, USA) with XbaI and NheI and blunt-cloning it into the pSTBlue-1 vector (Novagen, Madison, WI, USA), from which it was cut out using BamHI and AvrII and then inserted into the VA7 vector cut with the same enzymes.
Cell Viability Assay
Glioma cells were plated at 3×103 cells per well on a 96-well plate. VA7-EGFP at MOI 10−5–101 was added 16 hours later in a volume of 10 µl and the cells were incubated for 96 hours. Calcein AM was added to a final concentration of 1 µM and the cells were incubated for 12 minutes at 37°C, after which the wells were rinsed once with PBS and finally, 50 µl of PBS was pipetted to each well and fluorescence was measured with Victor 1420 Multilabel Counter (Perkin-Elmer Wallac, Turku, Finland).
Immunodetection of VA7-EGFP Structural Proteins
Glioma cells were seeded at 2×105 cells/well on a 6-well plate. Twenty hours later VA7-EGFP was added at an MOI of 1. After 18 hours the medium was removed and the samples were processed for Western analysis as described in .
MBA-13 cells were seeded on 6-well plates at 3×105/well. Tissue homogenates were added 24 hours later and incubation was continued for one hour. The medium was then replaced with a medium containing 0.5% FCS and 0.4% SeaPlaque agarose. After 48 hours the agarose was removed and the cell monolayers fixed and stained with crystal violet solution (0.2% crystal violet w/v, 5% formaldehyde and 1% ethanol).
Seven-to-eight-week-old female Balb/cOlaHsd Foxn1−/− mice were purchased from Harlan Laboratories (Allerod, Denmark) and housed in filter cages in groups of 4 mice per cage. Animal experiments were conducted in Turku and Kuopio, Finland, under experimental protocols approved by the Finnish National Review Board for Animal Experimentation.
Evaluation of VA7-EGFP Anti-Glioma Activity in Subcutaneous Tumor Model
To induce subcutaneous tumors, 5×106 U87Fluc cells in 100 µl of PBS were injected into the right flanks of nude Balb/c mice. Tumor length and width were measured every third day with a caliper and the tumor volumes were calculated from the equation (length×width2)/2. When the tumors reached ∼100 mm3, four mice received a single intravenous injection of PBS (control). A group of 5 mice received a single intravenous injection of 1×106 PFU of VA7-EGFP. The rest of the animals were left untreated until the average tumor size was 450 mm3, at which point a group of 6 mice received a single intravenous injection of 1×106 PFU VA7-EGFP while another group of 6 mice received three intravenous injections of VA7-EGFP, each 1×106 PFU, at 7-day intervals. Additional 7 mice with tumor sizes averaging 450 mm3 received either a single or three injections of VA7-EGFP and were used for histological studies. Animals were killed with CO2 when the tumor size reached 800 mm3.
Evaluation of VA7-EGFP Anti-Glioma Activity in Intracranial Tumor Model
U87Fluc cells were cultured as described above. Cells were detached with trypsin/EDTA, spun down, washed with PBS and suspended in PBS at 2×105 cells/3 µl. Mice were anesthetized with an intraperitoneal injection of ketamine (75 mg/kg) plus medetomidine (1 mg/kg). The animals were placed on a stereotactic apparatus (Stoelting, Wood Dale, IL, USA), the head was cleaned with 70% isopropanol solution and an incision was made along the midline. The skin was withdrawn to the sides and a burr hole with a diameter of 0.5 mm was drilled 0.5 mm anterior and 1.5 mm lateral to bregma. A 10 µl Hamilton syringe with a 30 gauge needle was mounted on the stereotactic frame and lowered to a depth of 3 mm at 1 mm/min. Two hundred thousand cells in 3 µl PBS were injected at 1 µl/min. After the injection was completed, the needle was kept in place for additional two minutes and then slowly withdrawn. The skin folds were closed with polyamide surgical thread and the animals were aroused with an i.p. injection of atipamezole (Antisedan, 1 mg/kg). Three weeks later the mice were imaged for intracranial Fluc activity. Mice with intracranial bioluminescence were randomly divided into three groups. A group of 6 mice was injected with PBS while another group of 5 mice received a single intravenous dose of 1×106 pfu of VA7-EGFP. Using the PBS group, an IVIS end point for sacrifice of the mice (1×109 photons/sec/cm2/steradian) was set to roughly one week before the appearance of clinical signs due to tumor burden.
VA7-Rluc Replication in Tumor-Bearing Nude Mice
U87FLuc tumor cells were implanted intracranially in 6 nude mice as described above and imaged for the presence of intracranial firefly bioluminescence 16 days later. Three bioluminescence positive mice were injected intravenously with 1×106 PFU of VA7-RLuc. The mice were imaged for Renilla bioluminescence at 16, 24, 40 and 96 hours post injection. After the last time point when Rluc signal had abated, the mice were imaged for Fluc activity and followed regularly until the termination of the study. Tumor signal in the remaining three tumor-bearing mice was monitored regularly until close to the IVIS endpoint upon which the mice received a single intravenous injection of 1×106 pfu of VA7-Rluc and were imaged as above. The experiment was repeated with 6 tumor-bearing mice which received a single injection of VA7-Rluc but this time only firefly bioluminescence was monitored.
In vivo Imaging
For detection of Fluc activity, mice were injected intraperitoneally with 150 µl of beetle luciferin (Promega, Madison WI, USA) at 2 µg/µl and anesthetized with a continuous 2.5% isoflurane flow. Ten minutes later, the animals were moved into IVIS 50 (Xenogen) apparatus chamber with ongoing anesthesia and 30 second images were acquired. For detection of VA7-Rluc, mice were injected intravenously with 100 µl of ViviRen substrate (Promega) at 0.2 µg/µl in 0.1% bovine serum albumin-PBS under continuous isoflurane anesthesia. Mice were imaged two minutes after substrate injection using data acquisition time of 3 minutes.
Mice were CO2 -euthanized and perfused intracardially with PBS. Organs were removed, fixed in paraformaldehyde, embedded in paraffin, sectioned and stained with hematoxylin and eosin, rabbit anti-SFV antibody (1∶3000) and polyclonal anti-luciferase antibody (1∶250, MBL Medical & Biological Laboratories Ltd, Nagoya, Japan) as described .
Characterization of Fluc expressing U87 glioma cells. A) U87 cells were transduced with the lentiviral vector WPTFluc at MOI 1 to 50 and the luciferase activities of the transduced cells were determined. B) U87 cells expressing Fluc were seeded on a 96-well plate and proliferation of the cells was measured during a 5-day period using calcein AM probe as an indicator of viable cells. Results are shown as the means and 95% confidence intervals. C) Oncolytic activity of VA7-EGFP on the parental U87 cells and cells which had been transduced with WPTFluc at MOI 25 (U87Fluc25) was investigated. VA7-EGFP was added to cells at MOI 10−3 to 1. Cell viability was measured 96 hours later using the calcein AM probe. The results are shown as the means and 95% confidence intervals. D) Flow cytometry analysis of U87 and U87Fluc cells detected with anti-luciferase antibody and Alex-488 -coupled secondary antibody.
(0.29 MB TIF)
Effect of intravenously administered VA7-EGFP on the weight of nude mice. Balb/c nude mice received a single intravenous injection of either PBS (n = 3) or 1×1E6 PFU of VA7-EGFP (n = 3). The animals were weighed every 6th day during a 48-day period. During this time period no neurological symptoms or other adverse effects in the virus-treated group was observed. The results are shown as the means and 95% confidence intervals.
(0.05 MB TIF)
Characterization of tumor cell explants from subcutaneous U87Fluc tumors. A) Cell lines established from subcutaneous U87Fluc tumors that had progressed after initial response were grown on cover slips and stained with anti-luciferase antibody followed by detection with Alexa 488-coupled secondary antibody. Left, fluorescence; right, phase contrast photomicrographs. B) Eight cell lines derived from 7 different subcutaneous tumors, which had regrown after VA7-EGFP treatment, were exposed to VA7-EGFP at increasing MOI. Also two cell lines derived from tumors of two PBS-treated mice as well as the parental cell line U87Fluc were exposed to the virus. Cell viability was measured 96h later using calcein AM probe. Sensitivities for VA7-EGFP-induced cell killing of the cells derived from VA7-EGFP-treated tumors fell between those of U87Fluc cells and cells derived from tumor of a PBS-treated mouse. Each data point is the mean of 6 determinations and the error bars are not shown for the sake of clarity.
(2.49 MB TIF)
VA7-Rluc replication in U87Fluc tumor-bearing mice. Orthotopic U87Fluc xenografts were established in nude mice by stereotactic injections of the tumor cells. When the firefly bioluminescence from the tumor xenografts reached appropriate levels the animals were given an intravenous injection of 1×1E6 PFU of VA7 expressing Renilla luciferase. After either 16 or 24 hours the animals were injected intravenously with Viviren substrate and the light produced by the VA7Rluc vector was monitored by a cooled CCD camera. Transient virus replication (Rluc) could be detected in the brain, co-localizing with the tumor (Fluc), as well as in the periphery. Virus signals can be compared with each other but not with tumor signal due to different intensity scale. Tumor signal was extinguished within 4 days, irrespective of the size of the tumor at the start of the treatment. In all but one mouse (nr. 5), tumor signal remained below detection limit at the end of the study. In another mouse (nr. 1), tumor regrowth followed by remission could be detected after day 4 post injection.
(4.04 MB TIF)
Hematoxylin and eosin staining of brain tissue of VA7-Rluc-treated mice 120 days after U87Fluc tumor implantation. After the final in vivo imaging the mice shown in figure 5 were intracardially perfused with PBS, the brains were removed and fixed in formalin and embedded in paraffin. Sagittal sections were prepared and stained with hematoxylin and eosin. For mouse 5, which was the only Fluc positive animal at the final measurement, a section taken 100 µm mediolateral from the one shown in Figure 5 is presented here. Also in this section signs of tissue defects are evident (boxed area) although no residual tumor cells can be distinguished. A tissue trauma is also evident in the brain of mouse 6 (boxed area). This site is most likely the original tumor site but no tumor cells can be detected in this section and nor were Fluc cells detected in other sections from this animal either. For mice 5 and 6 a 13× magnification of the trauma sites are shown on the right. Bar = 1.0 mm.
(5.61 MB TIF)
Effect of a single injection of VA7-Rluc on the growth of intracranial U87Fluc xenografts. U87Fluc cells were implanted stereotactically in Balb/c nude mice and the tumor growth was monitored by IVIS Imaging system. Eighteen days later the animals were given a single injection of 1×1E6 pfu of VA7-Rluc or PBS (controls). Of the virus-treated mice only one developed tumor after initial tumor regression (mouse 1). Rest of the animals stayed tumor-free for the rest of the follow-up period. Fluc bioluminescence in PBS-treated mice reached end point level in two weeks.
(3.61 MB TIF)
Hematoxylin and eosin staining of organs from VA7-treated mice. Left panel, Balb/c nude mice were injected with 1×1E6 PFU of VA7-Rluc and the animals were sacrificed at days 3, 6 and 9 after infection. Brain, heart, liver and spleen were removed for titration and histological analysis. Representative images of HE-stained organs from a mouse sampled at day 3 post infection. Right panel, organs from the VA7-Rluc-treated mice from the in vivo experiment shown in Figure S6 were removed at the termination of the study and cut in half. One half was frozen in liquid nitrogen for plaque assay and the other half was fixed in paraformaldehyde and processed for hematoxylin and eosin staining. Representative HE images from mouse 3 are shown. Original magnifications: brain×100, heart, spleen and liver×200.
(13.82 MB TIF)
The authors wish to thank Youngmin Choi, Michelle Becker, Femina Kanji, and Devin Tonelli at the Ottawa Health Research Institute and Sinikka Kollanus, Harri Kujari, Marja-Riitta Uola, and Jouko Sandholm at the University of Turku. The authors are also grateful to Ivana Kholová for evaluation of tissue pathology.
Conceived and designed the experiments: JEH MJVVK JCB AH. Performed the experiments: JEH MJVVK JJR MWM MMMS JAM. Analyzed the data: JEH MJVVK. Wrote the paper: JEH MJVVK AH.
- 1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987–996.
- 2. Pang BC, Wan WH, Lee CK, Khu KJ, Ng WH (2007) The role of surgery in high-grade glioma–is surgical resection justified? A review of the current knowledge. Ann Acad Med Singapore 36: 358–363.
- 3. Matsukado Y, MacCarthy CS, Kernohan JW (1961) The growth of glioblastoma multiforme (astrocytomas, grades 3 and 4) in neurosurgical practice. J Neurosurg 18: 636–644.
- 4. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683–2710.
- 5. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821–5828.
- 6. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756–760.
- 7. Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, et al. (2001) Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 93: 903–912.
- 8. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, et al. (2006) Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13: 221–228.
- 9. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854–856.
- 10. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1: 938–943.
- 11. Geoerger B, Vassal G, Opolon P, Dirven CM, Morizet J, et al. (2004) Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. Cancer Res 64: 5753–5759.
- 12. Lun X, Senger DL, Alain T, Oprea A, Parato K, et al. (2006) Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl Cancer Inst 98: 1546–1557.
- 13. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, et al. (2003) Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 63: 2462–2469.
- 14. Lun X, Yang W, Alain T, Shi ZQ, Muzik H, et al. (2005) Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res 65: 9982–9990.
- 15. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E (2000) Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci U S A 97: 6803–6808.
- 16. Lun XQ, Jang JH, Tang N, Deng H, Head R, et al. (2009) Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 15: 2777–2788.
- 17. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, et al. (2000) An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 6: 1134–1139.
- 18. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, et al. (2001) Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61: 8751–8757.
- 19. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, et al. (2000) Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821–825.
- 20. Krishnamurthy S, Takimoto T, Scroggs RA, Portner A (2006) Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 80: 5145–5155.
- 21. Coffey MC, Strong JE, Forsyth PA, Lee PW (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332–1334.
- 22. Strauss JH, Strauss EG (1994) The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 58: 491–562.
- 23. Mathiot CC, Grimaud G, Garry P, Bouquety JC, Mada A, et al. (1990) An outbreak of human Semliki Forest virus infections in Central African Republic. Am J Trop Med Hyg 42: 386–393.
- 24. Kokernot RH, Casaca VM, Weinbren MP, McIntosh BM (1965) Survey for antibodies against arthropod-borne viruses in the sera of indigenous residents of Angola. Trans R Soc Trop Med Hyg 59: 563–570.
- 25. Kolu-John EO, Fagbami AH (1983) Arthropod-borne virus antibodies in sera of residents of Kainji Lake Basin, Nigeria 1980. Trans R Soc Trop Med Hyg 77: 149–151.
- 26. Bradish CJ, Allner K, Maber HB (1971) The virulence of original and derived strains of Semliki forest virus for mice, guinea-pigs and rabbits. J Gen Virol 12: 141–160.
- 27. McIntosh BM, Worth CB, Kokernot RH (1961) Isolation of Semliki Forest virus from Aedes (Aedimorphus) argenteopunctatus (Theobald) collected in Portuguese East Africa. Trans R Soc Trop Med Hyg 55: 192–198.
- 28. Tuittila MT, Santagati MG, Röyttä M, Määttä JA, Hinkkanen AE (2000) Replicase complex genes of Semliki Forest virus confer lethal neurovirulence. J Virol 74: 4579–4589.
- 29. Fazakerley JK, Pathak S, Scallan M, Amor S, Dyson H (1993) Replication of the A7(74) strain of Semliki Forest virus is restricted in neurons. Virology 195: 627–637.
- 30. Fragkoudis R, Breakwell L, McKimmie C, Boyd A, Barry G, et al. (2007) The type I interferon system protects mice from Semliki Forest virus by preventing widespread virus dissemination in extraneural tissues, but does not mediate the restricted replication of avirulent virus in central nervous system neurons. J Gen Virol 88: 3373–3384.
- 31. Vähä-Koskela MJ, Tuittila MT, Nygårdas PT, Nyman JK, Ehrengruber MU, et al. (2003) A novel neurotropic expression vector based on the avirulent A7(74) strain of Semliki Forest virus. J Neurovirol 9: 1–15.
- 32. Vähä-Koskela MJ, Kallio JP, Jansson LC, Heikkilä JE, Zakhartchenko VA, et al. (2006) Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res 66: 7185–7194.
- 33. Otto-Duessel M, Khankaldyyan V, Gonzalez-Gomez I, Jensen MC, Laug WE, et al. (2006) In vivo testing of Renilla luciferase substrate analogs in an orthotopic murine model of human glioblastoma. Mol Imaging 5: 57–64.
- 34. Vähä-Koskela MJ, Heikkilä JE, Hinkkanen AE (2007) Oncolytic viruses in cancer therapy. Cancer Lett 254: 178–216.
- 35. Currier MA, Adams LC, Mahller YY, Cripe TP (2005) Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Ther 12: 407–416.
- 36. Grote D, Russell SJ, Cornu TI, Cattaneo R, Vile R, et al. (2001) Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 97: 3746–3754.
- 37. Kambara H, Okano H, Chiocca EA, Saeki Y (2005) An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65: 2832–2839.
- 38. Määttä AM, Liimatainen T, Wahlfors T, Wirth T, Vähä-Koskela M, et al. (2007) Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models. Int J Cancer 121: 863–870.
- 39. Amor S, Scallan MF, Morris MM, Dyson H, Fazakerley JK (1996) Role of immune responses in protection and pathogenesis during Semliki Forest virus encephalitis. J Gen Virol 77(Pt 2): 281–291.
- 40. Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21: 1624–1636.
- 41. Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, et al. (2007) Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 85: 133–148.
- 42. Camphausen K, Purow B, Sproull M, Scott T, Ozawa T, et al. (2005) Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions. Proc Natl Acad Sci U S A 102: 8287–8292.
- 43. Annabi B, Rojas-Sutterlin S, Laflamme C, Lachambre MP, Rolland Y, et al. (2008) Tumor environment dictates medulloblastoma cancer stem cell expression and invasive phenotype. Mol Cancer Res 6: 907–916.
- 44. Shah AC, Parker JN, Gillespie GY, Lakeman FD, Meleth S, et al. (2007) Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. Gene Ther 14: 1045–1054.
- 45. Ozduman K, Wollmann G, Piepmeier JM, van den Pol AN (2008) Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J Neurosci 28: 1882–1893.
- 46. Rodriguez-Madoz JR, Prieto J, Smerdou C (2007) Biodistribution and tumor infectivity of semliki forest virus vectors in mice: effects of re-administration. Mol Ther 15: 2164–2171.